OATP抑制大幅增加firsocostat血浆暴露但不改变药效或推断的肝细胞内暴露
本研究为随机四周期交叉药物相互作用试验,在28名健康志愿者中评估OATP抑制剂利福平对firsocostat(FIR)药代动力学和肝脏药效学的影响。结果显示,合用利福平使FIR血浆暴露(AUCinf)增加5.2倍,但肝脏DNL抑制效应无变化(单用FIR降低37.1%,FIR+利福平降低34.9%),提示OATP活性大幅下降不改变主要经肝消除且渗透速率受限药物的肝细胞内暴露。
要点
- OATP抑制使FIR血浆AUCinf增加5.2倍,但肝脏药效不变。
- 单用FIR和FIR+利福平的DNL抑制率分别为37.1%和34.9%。
- 结果支持肝靶向OATP底物在OATP功能降低时无需调整剂量。
核心结论
- OATP活性大幅降低不改变主要经肝消除且渗透速率受限药物(如FIR)的肝细胞内暴露,血浆暴露增加不代表肝内药效增强。
研究设计与样本
- 随机四周期交叉药物相互作用研究,28名健康志愿者纳入,24名完成,各周期间隔7天洗脱。
主要发现
- 单用利福平使肝脏DNL AUEClast增加35.7%。
- 合用利福平使FIR血浆AUCinf增加5.2倍。
- 单用FIR和FIR+利福平分别使DNL AUEClast降低37.1%和34.9%,两者药效无差异。
- 所有不良事件均为轻度。
关键数值与推荐
- FIR 10 mg单次口服,利福平300 mg静脉注射作为OATP抑制剂。
- 药效学指标为肝脏DNL AUEClast,药代动力学指标为FIR AUCinf。
临床怎么用
- 对于主要经肝消除且渗透速率受限的OATP底物肝靶向药物,在OATP功能降低时血浆暴露增加但肝内药效不变,提示无需因OATP抑制而调整剂量。
局限性
- 研究仅纳入健康志愿者,未在患者中验证。
- 样本量较小(24名完成),结论需进一步证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Firsocostat (FIR: previously GS-0976), a highly sensitive OATP substrate, reduces hepatic de novo lipogenesis (DNL) by inhibiting acetyl-CoA carboxylases (ACC). Measuring the pharmacodynamic (PD) efficacy of FIR on DNL provides a unique opportunity to determine optimal dosing strategies for liver-targeted OATP substrates in settings of altered OATP function. A randomized, four-way crossover drug-drug interaction study was conducted. Hepatic DNL, a marker for ACC activity, was measured in 28 healthy volunteers after reference, single dose FIR 10 mg, FIR 10 mg plus the OATP inhibitor rifampin (RIF) 300 mg i.v., or RIF 300 mg i.v. (control for DNL effect of RIF), each separated by a 7-day washout. Samples were collected for pharmacokinetic (PK) and PD assessments through 24 hours after each treatment. Hepatic DNL and its inhibition by FIR were assessed. Twenty-four subjects completed the study. All adverse events were mild. RIF alone increased hepatic DNL area under the effect curve from time of administration up to the time of the last quantifiable concentration (AUEClast ; 35.7%). Despite a 5.2-fold increase in FIR plasma exposure (area under the concentration-time curve from zero to infinity (AUCinf )) when administered with RIF, FIR alone, and FIR + RIF had the same hepatic PD effect, 37.1% and 34.9% reduction in DNL AUEClast , respectively, compared with their respective controls. These findings indicate that large decreases in OATP activity do not alter hepatic intracellular exposure (as inferred by no change in PD) for drugs that are primarily eliminated hepatically and permeability rate-limited, such as FIR. These results support PK theory that has been difficult to test and provide practical guidance on administration of liver-targeted drugs in settings of reduced OATP function.
引用
- Kirby BJ, Lutz JD, Yue MS, et al. Organic Anion Transporting Polypeptide Inhibition Dramatically Increases Plasma Exposure but not Pharmacodynamic Effect nor Inferred Hepatic Intracellular Exposure of Firsocostat. Clin Pharmacol Ther. 2020. PMID: 33141923. doi:10.1002/cpt.2105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。